Harrow, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow, Inc. on June 9, 2025. The report discloses a strategic business development involving a new license and supply agreement entered into on the same date.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data for a reporting period. The only specific financial figure disclosed relates to the new agreement:
- Upfront Payment Obligation: $500,000 payable to Formosa Pharmaceuticals, Inc. upon the Company's first commercial sale of the licensed product.
- Debt Instruments: The registrant has two classes of Senior Notes registered on The Nasdaq Stock Market LLC: 8.625% Senior Notes due 2026 (HROWL) and 11.875% Senior Notes due 2027 (HROWM).
Material Changes
The material change reported is the execution of a license and supply agreement with Formosa Pharmaceuticals, Inc. Key terms include:
- Product: Exclusive rights and marketing authorization for BYQLOVITM (clobetasol propionate ophthalmic suspension) 0.05% in the U.S. market.
- Payment Structure: A one-time payment of $500,000 triggered by the first commercial sale, plus potential future one-time payments based on commercial gross profit milestones and ongoing royalties on gross profits.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosure of the agreement terms. The agreement introduces contingent liabilities dependent on future commercial sales and gross profit milestones.
Investor Verification Checklist
- Verify the status of the first commercial sale of BYQLOVITM to determine if the $500,000 payment obligation has been triggered.
- Review the full text of the license and supply agreement (Exhibit 99) for details on royalty rates and specific gross profit milestone thresholds.
- Assess the impact of the new product launch on the company's existing debt service obligations for the 2026 and 2027 Senior Notes.
- Confirm the regulatory status and marketing authorization timeline for BYQLOVITM in the U.S. market.